Evusheld shows benefit in helping prevent illness and death among immunocompromised individuals who are unable to achieve an efficient response to COVID-19 vaccines.

Similar to other low- and middle-income countries, Thailand needs evidence on cost-effectiveness and budget impact to inform decision making with regard to the introduction of Evusheld and other expensive medicines to ensure the sustainability of universal health coverage (UHC).

As shown in the study results, a policy of screening the level of immunity before giving Evusheld can make Evusheld more cost effective.